Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Hydrocortisone as effective as triamcinolone for phimosis

06 Oct 2019
Circumcision has been a controversial issue debated in many countries

Over-the-counter hydrocortisone does not perform worse than triamcinolone for grade 4–5 phimosis, a recent study has found.

Researchers randomly assigned boys aged 3–13 years with phimosis to receive either 0.1% triamcinolone (n=19; mean age, 6.6±2.1 years) or 1% hydrocortisone (n=13; mean age, 5.9±2.5 years). Evaluations were performed at weeks 4, 8 and 12, and treatment success was defined as reaching disease grade 2 after 12 weeks of treatment. Only those with grade 3–4 condition at baseline were eligible for inclusion.

In the hydrocortisone group, 30.8 percent (n=4) were successfully treated by week 4. Over the same time span, 31.6 percent (n=6) of the triamcinolone group had been successfully treated. The corresponding rates in either group increased to 53.8 percent and 52.6 percent by week 8 and 61.5 percent and 68.4 percent by week 12.

Between-group differences in success rates failed to reach statistical significance at any time point (week 4: p=0.99; week 8: p=0.99; week 12: p=0.72). The same was true for adherence.

Similarly, patient age (p=0.16) and a prior history of balanitis had no significant effects on the likelihood of treatment success. Having grade 4 or 5 phimosis at baseline was similarly unrelated to the odds of successful treatment (p=0.27).

No adverse events were reported.

The present study shows that topical corticosteroids remain effective for the treatment for phimosis, and that there appears to be no significant relative superiority of one over others. Treatment duration, on the other hand, seems to be a more important factor, such that prolonged topical exposure may lead to greater chances of success, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.